{"id":"alx-0081","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4297692","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By binding to the A1 domain of vWF, ALX-0081 inhibits the interaction between vWF and platelets, which is crucial for thrombus formation under high shear stress conditions.","oneSentence":"ALX-0081 is a nanobody that specifically targets von Willebrand factor (vWF), reducing its activity and preventing platelet aggregation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:45.516Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acquired thrombotic thrombocytopenic purpura (aTTP)"}]},"trialDetails":[{"nctId":"NCT04074187","phase":"PHASE2, PHASE3","title":"A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-21","conditions":"Thrombotic Thrombocytopenic Purpura","enrollment":21},{"nctId":"NCT02553317","phase":"PHASE3","title":"Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2015-11","conditions":"Acquired Thrombotic Thrombocytopenic Purpura","enrollment":145},{"nctId":"NCT01151423","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2011-01","conditions":"Acquired Thrombotic Thrombocytopenic Purpura","enrollment":75},{"nctId":"NCT01020383","phase":"PHASE2","title":"Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2009-09","conditions":"Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI), Stable Angina (Associated With High Risk PCI)","enrollment":364},{"nctId":"NCT02878603","phase":"PHASE3","title":"Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-10-06","conditions":"Acquired Thrombotic Thrombocytopenic Purpura","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ALX-0081","genericName":"ALX-0081","companyName":"Ablynx, a Sanofi company","companyId":"ablynx-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALX-0081 is a nanobody that specifically targets von Willebrand factor (vWF), reducing its activity and preventing platelet aggregation. Used for Acquired thrombotic thrombocytopenic purpura (aTTP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}